Skip to main
BMY
BMY logo

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 15%
Hold 62%
Sell 8%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb's positive outlook is supported by potential catalysts such as positive clinical data from the Cobenfy ADEPT-2 trial and anticipated faster growth in the company's Growth Portfolio, indicating strong revenue prospects. Additionally, positive developments in CD19 NEX-T data for broader autoimmune diseases could enhance their market position and lead to advancements into pivotal studies. Despite some recent negative optics regarding top-line data, underlying supportive trends and key opinion leader (KOL) feedback suggest sustained growth in drug usage, further reinforcing the company's growth trajectory.

Bears say

Bristol-Myers Squibb's recent announcement regarding the Cobenfy drug demonstrated disappointing top-line data, falling short of statistical significance in the adjunctive schizophrenia setting, which raises concerns about the drug's commercial viability. The company's reliance on a narrow segment of its late-stage pipeline, particularly the ADEPT-2 trial, introduces significant downside risks, including the potential for delays and negative results that could further impact future growth and sales. Furthermore, with approximately 70% of sales derived from the US market, Bristol's heavy dependence heightens vulnerability to local market fluctuations and competition, exacerbating the overall negative outlook on its stock performance.

Bristol-Myers (BMY) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Hold based on their latest research and market trends.

According to 13 analysts, Bristol-Myers (BMY) has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.